Maze Therapeutics (NASDAQ:MAZE) Announces Earnings Results

Maze Therapeutics (NASDAQ:MAZE) released its earnings results on Tuesday. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76), Zacks reports.

Maze Therapeutics Trading Up 0.1%

Shares of Maze Therapeutics stock traded up $0.03 during trading on Tuesday, hitting $27.31. The company’s stock had a trading volume of 379,878 shares, compared to its average volume of 669,188. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.22. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. Maze Therapeutics has a 52 week low of $12.81 and a 52 week high of $53.65. The stock has a 50-day moving average price of $27.57 and a two-hundred day moving average price of $33.44.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on MAZE shares. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Truist Financial decreased their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $66.00.

Insider Transactions at Maze Therapeutics

In other news, CMO Harold Bernstein sold 15,000 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $26.22, for a total transaction of $393,300.00. Following the completion of the sale, the chief marketing officer directly owned 15,000 shares in the company, valued at $393,300. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the completion of the transaction, the chief executive officer owned 23,337 shares in the company, valued at approximately $699,643.26. The trade was a 59.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 141,470 shares of company stock worth $3,902,714 over the last ninety days. 5.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Maze Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company bought a new position in Maze Therapeutics during the fourth quarter worth $286,000. Persistent Asset Partners Ltd bought a new stake in Maze Therapeutics in the 4th quarter valued at about $274,000. Police & Firemen s Retirement System of New Jersey boosted its holdings in Maze Therapeutics by 18.5% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after acquiring an additional 931 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Maze Therapeutics by 85.2% during the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,078 shares of the company’s stock valued at $235,000 after acquiring an additional 4,177 shares in the last quarter. Finally, Rafferty Asset Management LLC acquired a new stake in Maze Therapeutics in the 4th quarter valued at $217,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.